Skip to main content

InvestorNewsBreaks – Processa Pharmaceuticals Inc. (NASDAQ: PCSA) Releases Shareholder Letter

Processa Pharmaceuticals (NASDAQ: PCSA), a clinical-stage pharmaceutical company focused on developing the next generation of chemotherapeutic drugs to improve the efficacy and safety for patients suffering from cancer, has released a shareholder letter from CEO Georg Ng. In the letter, Ng notes that because he was recently appointed CEO, he wanted investors to get a corporate update from the “new voice.” Ng confirmed that the company’s focus on the development of next-generation chemotherapy (“NGC”) agents will not change as chemotherapy drugs remain an important and viable treatment option for cancer. Ng noted that issues and limitations are often associated with the use of chemotherapy and that Processa can address these challenges by providing patients with potentially safer and more effective chemotherapy treatments through NGCs. The letter included an overview of the three NGCs currently in development: NGC-Capecitabine (PCS6422), NGC-Gemcitabine (PCS3117) and NGC-Irinotecan (PCS11T).

He also articulated Processa’s forward-looking vision, recapped the company’s experience team and provided an overview of the company’s stable financial situation and business development opportunities. “I feel that Processa is well-positioned for success and is uniquely positioned to disrupt and expand current chemotherapy and oncology therapeutics,” said Processa Pharmaceuticals CEO George Ng in the shareholder letter. “To that end, we are looking forward to our upcoming meeting with the FDA and to potentially releasing top-line data during the second half of December. Regarding Processa’s pivot to focus on oncology drug development, change forces adaptation that can be stewarded by effective leadership. My intention as the new CEO is to promote, encourage and facilitate advancement in the areas in which we excel. With our potentially revolutionary NGC drug products, Processa is poised to be a global leader in chemotherapy and oncology, and I am incredibly honored to have the opportunity to lead Processa through this transition and work to create shareholder value.”

To view the full press release, visit

About Processa Pharmaceuticals Inc.

Processa is a clinical-stage pharmaceutical company focused on developing next-generation chemotherapy (“NGC”) drugs to improve the safety and efficacy of cancer treatment. By combining Processa’s novel oncology pipeline with proven cancer-killing active molecules and the Processa Regulatory Science Approach as well as experience in defining optimal dosage regimens for FDA approvals, Processa not only will be providing better therapy options to cancer patients but also will increase the probability of FDA approval for its next-generation chemotherapy drugs. Processa’s NGC drugs are modifications of existing FDA-approved oncology drugs resulting in an alteration of the metabolism and/or distribution of these FDA-approved drugs while maintaining the existing mechanisms of killing the cancer cells. The company’s approach to drug development is based on more than 30 years of drug-development expertise to efficiently design and conduct clinical trials that demonstrate a positive benefit/risk relationship. Using its proven Regulatory Science Approach, the Processa team has experience defining the optimal dosage regimen using the principles of the FDA’s Project Optimus Oncology initiative. The advantages of Processa’s NGC drugs are expected to include fewer patients experiencing side effects that lead to dose discontinuation; more significant cancer response; and a greater number of patients, in excess of 200,000 for each NGC drug, who will benefit from each NGC drug. Currently under development are three next-generation chemotherapy oncology treatments: Next Generation Capecitabine (PCS6422 and capecitabine to treat metastatic colorectal, gastrointestinal, breast, pancreatic and other cancers), Next Generation Gemcitabine (PCS3117 to treat pancreatic, lung, ovarian, breast and other cancers), and Next Generation Irinotecan (PCS11T to treat lung, colorectal, gastrointestinal, pancreatic and other cancers). For more information, visit the company’s website at

NOTE TO INVESTORS: The latest news and updates relating to PCSA are available in the company’s newsroom at

About InvestorWire

InvestorWire (“IW”) is a specialized communications platform with a focus on advanced wire-grade press release syndication for private and public companies and the investment community. It is one of 60+ brands within the Dynamic Brand Portfolio @ IBN that delivers: (1) access to a vast network of wire solutions via InvestorWire to efficiently and effectively reach a myriad of target markets, demographics and diverse industries; (2) article and editorial syndication to 5,000+ outlets; (3) enhanced press release enhancement to ensure maximum impact; (4) social media distribution via IBN to millions of social media followers; and (5) a full array of tailored corporate communications solutions. With broad reach and a seasoned team of contributing journalists and writers, IW is uniquely positioned to best serve private and public companies that want to reach a wide audience of investors, influencers, consumers, journalists and the general public. By cutting through the overload of information in today’s market, IW brings its clients unparalleled recognition and brand awareness. IW is where breaking news, insightful content and actionable information converge.

For more information, please visit

Please see full terms of use and disclaimers on the InvestorWire website applicable to all content provided by IW, wherever published or re-published:

Los Angeles, CA
310.299.1717 Office

InvestorWire is powered by IBN

Data & News supplied by
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.